rs121913500
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
|
|
|
rs121913499
|
|
|
0.720 |
GeneticVariation |
UNIPROT |
|
|
|
rs104894156
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs1064794096
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs1554893792
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs63751110
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs786202398
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs1346787
|
|
|
0.030 |
GeneticVariation |
BEFREE |
<i>EFEMP1</i> rs1346787 polymorphism was significantly associated with glioma risk in Chinese population under all genetic models (GG vs AA, OR =2.22, 95% CI =1.46-3.36; AG vs AA, OR =1.54, 95% CI =1.27-1.87; (GG+AG) vs AA, OR =1.60, 95% CI =1.34-1.93; GG vs (AG+AA), OR =1.86, 95% CI =1.24-2.78; G vs A, OR =1.54, 95% CI =1.32-1.79).
|
29158681 |
2017 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<i>IDH1</i> mutations only affected brainstem gliomas (6/24 vs 0/78; <i>p</i> = 7.5 × 10<sup>-5</sup>), were mostly non-R132H (contrasting with hemispheric gliomas, <i>p</i> = 0.0001), and were associated with longer survival (54 vs 12 months).
|
29728520 |
2018 |
rs1045485
|
|
|
0.020 |
GeneticVariation |
BEFREE |
D302H polymorphism of CASP8 gene may be associated with increased risk of glioma but larger study groups in different ethnic populations are needed to better elucidate the role of CASP8 gene polymorphism in the pathogenesis of primary brain tumors.
|
26359420 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |
rs498872
|
|
|
0.900 |
GeneticVariation |
BEFREE |
A single nucleotide polymorphism (SNP) at locus 11q23.3 (rs498872) in the near 5'-UTR of the PHLDB1 gene was recently implicated as a risk factor for gliomas in a genome-wide association study, and this involvement was confirmed in three additional studies.
|
23300798 |
2012 |
rs25489
|
|
|
0.090 |
GeneticVariation |
BEFREE |
A total of 11 studies (3,810 cases and 6,079 controls), 7 studies (2,928 cases and 5,048 controls), and 4 studies (1,461 cases and 2,593 controls) were finally included in the analyses of the association between XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms and glioma risk, respectively.
|
23167420 |
2012 |
rs2289591
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A variant in PER1 (rs2289591) was significantly associated with overall glioma risk (per variant allele OR 0.80; 95 % CI 0.66-0.97; p trend = 0.027).
|
24135790 |
2014 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Activated leukocyte adhesion molecule expression in gliomas was independent of proliferative activity, MGMT status, patient survival, and age, whereas gliomas with IDH1 (R132H) mutation had significantly higher activated leukocyte adhesion molecule levels than their wild-type counterparts.
|
22304788 |
2012 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Additionally, 5-aza enhances the therapeutic effect of the DNA damaging agent TMZ in both subcutaneous and orthotopic PDX models of IDH1 R132H mutant glioma.
|
30184215 |
2019 |
rs118101777
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Additionally, 5-aza enhances the therapeutic effect of the DNA damaging agent TMZ in both subcutaneous and orthotopic PDX models of IDH1 R132H mutant glioma.
|
30184215 |
2019 |
rs7115578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs7115578 AG genotype represented a poorer prognosis of glioma (HR = 1.24, P=0.033) and astrocytoma (log-rank P=0.037, HR = 1.31, P=0.036).
|
31652449 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma.
|
28534272 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma.
|
28534272 |
2018 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additionally, subgroup analyses of 8 SNPs by ethnicity indicated that the mutation of rs13181, rs1800067 were apparently protective factors of glioma among Asians, while the mutation of rs13181 was a risk factors of glio</span>ma in Caucasians.
|
26843108 |
2017 |
rs1800067
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Additionally, subgroup analyses of 8 SNPs by ethnicity indicated that the mutation of rs13181, rs1800067 were apparently protective factors of glioma among Asians, while the mutation of rs13181 was a risk factors of glioma in Caucasians.
|
26843108 |
2017 |
rs11979158
|
|
|
0.850 |
GeneticVariation |
BEFREE |
Additionally, subgroup analysis by stages of glioma found that variation of rs11979158 had stronger relationship with high-grade (OR = 1.32, 95 %CI = 1.19-1.45) than low-grade glioma (OR = 1.12, 95 % CI = 1.03-1.21).
|
26243184 |
2016 |
rs2236661
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, two novel SNPs (rs2236661 and rs494560) that were independent of rs17749 were significantly associated with glioma risk in a recessive genetic model [P = 1.31×10⁻⁵ and P = 3.32×10⁻⁵, respectively].
|
23300798 |
2012 |